Solid Biosciences Inc. (SLDB)

Market Cap	324.71M
Revenue (ttm)	n/a
Net Income (ttm)	-96.02M
Shares Out	37.76M
EPS (ttm)	-4.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,141
Open	8.52
Previous Close	8.54
Day's Range	8.41 - 8.81
52-Week Range	1.81 - 15.05
Beta	1.94
Analysts	Strong Buy
Price Target	18.14 (+111.05%)
Earnings Date	May 9, 2024

About SLDB

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which help...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2018
• Employees: 88
• Stock Exchange: NASDAQ
• Ticker Symbol: SLDB

Analyst Forecast

According to 7 analysts, the average rating for SLDB stock is "Strong Buy." The 12-month stock price forecast is $18.14, which is an increase of 111.05% from the latest price.

Price Target

$18.14

(111.05% upside)

Analyst Consensus: Strong Buy